NEW YORK — Idenix Pharmaceuticals Inc. fell the most ever in Nasdaq trading after two experimental hepatitis C drugs were placed on hold by US regulators because they produced adverse effects in testing.
Idenix fell $2.81, or 47 percent, to $3.18.
The experimental drugs, IDX184 and IDX320, caused three serious adverse events when tested together in healthy volunteers, Cambridge, Mass.-based Idenix said in a statement yesterday. The Food and Drug Administration said the testing should stop after the two in combination caused abnormal liver function.
“We will be focusing all necessary resources at Idenix at supplying the FDA with all the data and information they need to help us resolve this clinical hold as quickly as possible, hopefully by the end of the year,’’ said Idenix chief executive Jean-Pierre Sommadossi.
